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The “middle child” of heart failure (patients with left ventricular ejection fraction [EF] in 
the 40-50% range) was christened heart failure with mid-range EF in 2014,1 in 
recognition of the large gap in treatment evidence in this neglected subgroup of heart 
failure, with prior clinical trial evidence limited to those patients with EF of 40% or 
lower, and recent attention being showered upon those with EF of 50% or greater. While 
the EF 40-50% group was recognized as a “grey area” in prior European Society of 
Cardiology Heart Failure Guidelines,2 the name “heart failure with mid-range EF” and 
acronym “HFmrEF” was adopted in the 2016 guidelines,3 with the intention of bringing 
attention to this group of patients and addressing the evidence gap. The adoption of this 
nomenclature has inspired hundreds of publications which show that HFmrEF constitutes 
almost a fifth of the heart failure population, with patient demographics intermediate 
between those with lower and higher EFs, high frequency of coronary artery disease, and 
better prognosis than those with lower EF.4  
 
Importantly, the naming of HFmrEF also prompted a relook at prior randomized 
controlled trials in heart failure over a broad range of EFs, suggesting that patients with 
ejection fraction in the lower portion of the HFpEF range, including those who would fall 
into the HFmrEF (EF 40-50%) category, may benefit from mineralocorticoid 
antagonists,5 angiotensin receptor blockers,6 beta-blockers7 and digoxin;8 similar to 
patients with EF<40% and distinct from patients with higher EF. More recently in the 
largest outcomes trial of heart failure with EF≥45% to date, the PARAGON-HF trial 
(Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin 
Receptor Blocker Global Outcomes in Heart Failure and Preserved Left Ventricular 
Ejection Fraction),9 a significant EF-by-treatment interaction was observed, whereby 
sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary 
composite outcome of cardiovascular death and total heart failure hospitalizations by 
22% in those with EF below the median of 57% (hazard ratio [HR] 0.78; 95% confidence 
interval [CI] 0.64–0.95), but with essentially no effect on the composite primary outcome 
in those with EF>57% (HR 1.00; 95% CI 0.81–1.23). Taken in the context of robust trial 
evidence of the benefit of neurohormonal agents in heart failure with EF<35-40%, 
including sacubitril/valsartan in the Prospective Comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) 
trial, these data suggest that prior trials may have used too low a cutoff of EF to define 
“reduced” EF (a cutoff that was itself arbitrarily chosen to enrich for events), and that 
patients with EF lower than normal, who probably benefit from such therapies, may in 
fact be more appropriately renamed as “heart failure with mildly reduced EF”.  
 
Beyond nomenclature, the recent trial evidence also call to question the cutoffs with 
which we define “mildly reduced” EF. As a continuous variable with a normal 
distribution within the population, the threshold value to define “normal” versus 
“reduced” EF is arbitrary. Guidelines from the American Society of Echocardiography 
and European Society of Echocardiography define a normal EF as >55%. Indeed, 
Framingham Heart Study participants with EF 50-55% were at greater risk of HF and 
death compared to those with EF>55%.7 Notably, the “normal” distribution of EF rises 
with age and is higher in women than men in the general population,10 since EF is a 
fraction which increases as the heart remodels and left ventricular end-diastolic volume 
(denominator) shrinks out of proportion to the stroke volume (numerator). Using a 
common EF cutoff of, say, 50% to define “normal” would therefore include elderly 
women who actually have relatively reduced EF for their age and sex. Such sex 
differences may explain the observation in the TOPCAT (Treatment of Preserved Cardiac 
Function Heart Failure with an Aldosterone Antagonist) trial, where women appeared to 
benefit across the EF spectrum beyond 55%, but men only at EF lower than ~55%.5 
Further supporting this concept, in combined PARAGON-HF and PARADIGM-HF 
data,11 treatment effect splines across the entire EF spectrum showed efficacy of 
sacubitril/valsartan in the EF 40-50% range, with the upper 95% confidence interval 
boundary of the rate ratio for sacubitril/valsartan versus comparator renin-angiotensin 
blockade remaining below 1.0 (indicating benefit with sacubitril/valsartan) up to EF 
~55%, and sex-specific splines indicating that the benefit of sacubitril/valsartan persisted 
to higher EFs in women compared to men.12 While such approaches may provide 
clinically meaningful evidence for an EF cutoff selection that was previously based on 
available trial evidence,13 we acknowledge that these post-hoc analyses should be 
regarded as hypothesis-generating only. We further acknowledge the potential for age- 
and ethnicity- specific EF cutoffs in addition to sex; yet heart failure is largely a disease 
of the elderly and robust evidence for ethnic heterogeneity of treatment response in heart 
failure is lacking. 
 
Pertinent to any discussion on EF cutoffs are the considerations that (i) the methods by 
which we measure EF are known to be imprecise, and (ii) EF measurements can change 
over time in the same patient.13, 14 The reliability of EF determination by 
echocardiography —the technique most commonly used clinically— showed an 
interobserver variability of 8% to 21% and an intraobserver variability of 6% to 13%.15 
Furthermore, while there were minor differences in EF measured by echocardiography 
compared to cardiac magnetic resonance imaging, left ventricular volumes by 
echocardiography were smaller and more variable than those obtained by cardiac 
magnetic resonance imaging.16 Added to this, EF has been shown to change over time in 
patients with heart failure, with more than a third of patients crossing the EF 50% 
threshold in either direction during longitudinal surveillance.17 Thus, the strict application 
of cutoffs to individual patients has a high potential for mis-classification. Given these 
considerations, is it meaningful in the first place to classify patients using EF? Such 
discussions have been raised time and again, reminiscent of the discussion of blood 
pressure cutoffs with which to define hypertension; and calls have been made to shift to 
etiology-based classification of heart failure instead of EF. Yet at the end of the day, EF 
remains a cornerstone of all current heart failure guidelines and the most clinically useful 
criterion to guide treatment decisions in clinical practice, since clinical trials that form the 
basis of evidence-based treatment recommendations are all predicated on EF cutoffs.   
 
If classification of heart failure by EF is here to stay (at least for the near future), how 
may we use more recent insights to better inform our classification using EF?18 A 
simplification to two instead of three categories, by lumping HFmrEF under “reduced” 
EF (using a cutoff of, say, <50%), would appear most straightforward and easy to 
implement.19 Indeed, the Australian 2018 heart failure guidelines came to this 
conclusion.20 However, grouping patients with “mildly reduced” and more severely 
reduced EF under the same umbrella would fail to recognize the different magnitudes of 
treatment effect and their strengths of evidence, as well as the different prognosis and 
risk-benefit ratios, in HFmrEF versus those with lower EFs. On the other hand, grouping 
patients with EF below 50% (or 55%) under the common term “reduced”, while still 
distinguishing between those with “mildly reduced” versus more severely reduced EF, 
would acknowledge the smaller relative and absolute benefits, as well as the lower 
strength of evidence, of neurohormonal antagonists in HFmrEF compared to heart failure 
with EF<40%. Of note, the Australian 2018 heart failure guidelines20 gave different 
strength of recommendations and quality of evidence for heart failure with a moderately/ 
severely reduced EF (<40%) (Strong recommendation/ High quality of evidence) 
compared to heart failure with mildly reduced EF (41-49%) (Weak recommendation/ 
Low or very low quality of evidence) for various neurohormonal therapies.  
 
Thus, a renaming of HFmrEF as “heart failure with mildly reduced EF” might solve some 
of these issues of nomenclature. While it is tempting to prescribe specific EF cutoffs, we 
recognize that there will be debate about what constitutes “mildly reduced”, what these 
cutoffs should be, and whether they should be different for men and women. 
Nevertheless, the new nomenclature would send an important signal to clinicians to 
consider treating these patients with neurohormonal agents known to be beneficial in 
patients with heart failure and more severely reduced EF, thus enlarging the treatment 
population and reducing the risk that patients with mildly reduced EF, especially women, 
who are deprived of potentially beneficial therapies. Such reclassification would 
accordingly shrink the population of heart failure with higher EFs for which we still have 
no evidence of treatment outcome benefits – a group perhaps aptly named “heart failure 
with normal EF (≥50 or 55% in men and ≥55 or 60% in women)” although precise 
cutoffs remain controversial since “normal” EF may also vary with factors other than sex 
(such as age and ethnicity). Furthermore, the presence of a very high EF should prompt a 
search for pathology, such as cardiac amyloidosis or hypertrophic cardiomyopathy, where 
shrinkage of the left ventricular end-diastolic volume (denominator of EF) leads to 
“supra-normal” EF.21 Any revised nomenclature would impact estimates of prevalence 
and incidence of the different forms of heart failure, carrying implications for resource 
utilization that healthcare providers, regulators and payers will need to grapple with.  
 
Given the totality of the evidence, we propose renaming "heart failure with mid-range 
ejection fraction" as “heart failure with mildly reduced ejection fraction” and considering 
sex-based cutoffs in the definition. The implications of this new nomenclature are three-
fold: (i) attempts should be made to obtain as precise a measurement of EF as possible in 
patients with heart failure, especially in those whose EF measurements are borderline, to 
avoid misclassification; (2) patients with a mildly reduced EF should be given the benefit 
of the doubt and considered for treatment with established therapies in HF with more 
severely reduced EF; (3) future clinical trials for heart failure with reduced EF may 
consider enrolling patients with EF up to the normal range. 
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